Loading patent…
AssigneesE.R. Squibb & Sons, Inc., Ono Pharmaceutical Co., Ltd.
InventorsAlan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
Estimating the term…
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
A method of treating a tumor in a subject in need thereof comprising administering a therapeutic dose of a human or humanized anti-PD-1 antibody or an antigen-binding portion thereof to the subject, wherein an anti-CTLA-4 antibody or an antigen-binding portion thereof has been administered to the subject prior to the administration of the anti-PD-1 antibody or antigen-binding portion thereof, wherein the administration of the anti-PD-1 antibody or antigen-binding portion thereof treats the tumor in the subject.
Dependencies are inferred from the claim text.